Systems and methods for mechanogenetic functional ultrasound imaging
US-12172037-B2 · Dec 24, 2024 · US
US10047136B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10047136-B2 |
| Application number | US-201715688983-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 29, 2017 |
| Priority date | Sep 11, 2012 |
| Publication date | Aug 14, 2018 |
| Grant date | Aug 14, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention discloses cryopreserved recombinant cells for screening drug candidates that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. Advantageously, such cells provide a cost-efficient consumable product that streamlines the process of screening whether drug candidates are substrates or inhibitors of drug transporter proteins and/or drug metabolizing enzymes.
Opening claim text (preview).
What is claimed is: 1. A cryopreserved recombinant cell comprising one or more transiently overexpressed genes encoding a drug transporter protein, wherein activity of the drug transporter protein is detectable in a population of the cryopreserved recombinant cell following thaw from cryopreservation, wherein the cryopreserved recombinant cell is transiently transfected with the one or more genes by a method comprising electroporation, and wherein said one or more genes is OAT3 and wherein said cell is HEK293. 2. The recombinant cell of claim 1 , wherein said one or more genes is derived individually from human or an animal species selected from mouse, rat, guinea pigs, dog, and monkey. 3. The recombinant cell of claim 1 , wherein activity of the drug transporter protein is detectable in a population of said cell at least 24 hours post plating following thaw from cryopreservation. 4. The recombinant cell of claim 1 , wherein activity of the drug transporter protein is detectable in a population of said cell at least 48 hours post plating following thaw from cryopreservation. 5. The recombinant cell of claim 1 , wherein activity of the drug transporter protein is detectable in a population of said cell at least 72 hours post plating following thaw from cryopreservation. 6. A process of preparing cryopreserved transiently transfected recombinant cells, the process comprising: transiently transfecting cells with one or more genes encoding a drug transporter protein to provide the transiently transfected recombinant cells; and cryopreserving the transiently transfected recombinant cells within 48 hours of transfection, wherein the transient transfection of the cells comprises electroporation; wherein said one or more genes is OAT3 and wherein said cell is HEK293. 7. The process of claim 6 , wherein the transiently transfected recombinant cells are cryopreserved at 30 minutes to 24 hours post transfection. 8. A cryopreserved transiently transfected recombinant cell prepared according to the process of claim 6 .
using communication transmission lines {(G08B13/19658, G08B21/0286, G08B25/016 take precedence)} · CPC title
Alarm cancelling procedures or alarm forwarding decisions, e.g. based on absence of alarm confirmation · CPC title
Domotique, domestic, home control, automation, smart house · CPC title
Signal analysis techniques for reducing or preventing false alarms or for enhancing the reliability of the system · CPC title
electric · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.